Form 4: Entrada Therapeutics CFO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Entrada Therapeutics CFO Kory James Wentworth sold 7,988 shares of common stock for a weighted average price of $12.2549 per share.
Summary
- Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), reported a sale of common stock.
- The transaction involved the disposition of 7,988 shares of common stock.
- The shares were sold at a weighted average price of $12.2549 per share, with individual transaction prices ranging from $11.80 to $12.57.
- Following this transaction, Kory James Wentworth beneficially owns 137,987 shares of common stock.
- The sale was executed on March 4, 2026, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale was conducted under a pre-arranged 10b5-1 plan, which typically indicates a routine financial management decision rather than a reaction to new company-specific information.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
StockSavvy.ai notes that insider sales executed under a Rule 10b5-1 trading plan are a common practice in the biotechnology industry, allowing executives to diversify holdings or manage liquidity in a pre-scheduled, compliant manner, reducing the perception of trading on material non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The reported transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on March 6, 2025. This plan allows insiders to pre-arrange sales of company stock to avoid accusations of insider trading. | 03/06/2025 | Enhances transparency and compliance for insider stock transactions, aligning with best practices in corporate governance. |
Stakeholder Impact
- Shareholders: The sale is a routine insider transaction under a pre-arranged plan and is unlikely to have a significant direct impact on shareholder sentiment or company operations.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 03/04/2026 | Date of the reported transaction (sale of common stock). |
| 03/06/2026 | Date the Form 4 was signed by the Attorney-in-Fact. |
Recommendation
holdThe reported transaction is a routine insider sale executed under a pre-established Rule 10b5-1 trading plan. Such sales are typically for personal financial planning and do not usually signal a change in the company's fundamentals or management's outlook. Therefore, a 'hold' recommendation is appropriate as this event alone does not provide a strong basis for a buy or sell decision.
Keywords
Entrada Therapeutics, TRDA, Insider Trading, Form 4, Stock Sale, CFO, 10b5-1 Plan, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.